Zoledronic acid Mylan

zoledronic acid

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Zoledronic acid Mylan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Mylan.

What is Zoledronic acid Mylan?

Zoledronic acid Mylan is a medicine that contains the active substance zoledronic acid. It is available as a 4-mg/5-ml concentrate for solution for infusion.

Zoledronic acid Mylan is a ‘generic medicine’. This means that Zoledronic acid Mylan is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Zometa.

What is Zoledronic acid Mylan used for?

Zoledronic acid Mylan can be used to prevent bone complications in adults with advanced cancer that is affecting the bone. This includes fractures (breaks in the bone), spinal compression (when the spinal cord is compressed by the bone), bone disorders needing radiotherapy (treatment with radiation) or surgery, and hypercalcaemia (high levels of calcium in the blood). Zoledronic acid Mylan can also be used to treat the hypercalcaemia caused by tumours.

The medicine can only be obtained with a prescription.

How is Zoledronic acid Mylan used?

Zoledronic acid Mylan must only be used by a doctor who has experience in the use of this type of medicine given into a vein.

The usual dose of Zoledronic acid Mylan is one infusion of 4 mg over at least 15 minutes. When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys. It is not recommended for patients with severe kidney problems.

How does Zoledronic acid Mylan work?

The active substance in Zoledronic acid Mylan, zoledronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

Patients with tumours can have high levels of calcium in their blood, released from the bones. By preventing the breakdown of bones, Zoledronic acid Mylan also helps to reduce the amount of calcium released into the blood.

How has Zoledronic acid Mylan been studied?

The company provided data from the published literature on zoledronic acid. No additional studies in patients were needed as Zoledronic acid Mylan is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.

What are the benefits and risks of Zoledronic acid Mylan?

Because Zoledronic acid Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why has Zoledronic acid Mylan been approved?

The CHMP concluded that, in accordance with EU requirements, Zoledronic acid Mylan has been shown to have comparable quality and to be bioequivalent to Zometa. Therefore, the CHMP’s view was that, as for Zometa, the benefit outweighs the identified risk. The Committee recommended that Zoledronic acid Mylan be given marketing authorisation.

Other information about Zoledronic acid Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Mylan on 23 August 2012.

For more information about treatment with Zoledronic acid Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Zoledronic acid Mylan : EPAR - Summary for the public BG = bălgarski 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public ES = español 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public CS = čeština 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public DA = dansk 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public DE = Deutsch 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public ET = eesti keel 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public EL = elliniká 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public EN = English 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public FR = français 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public IT = italiano 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public LV = latviešu valoda 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public LT = lietuvių kalba 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public HU = magyar 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public MT = Malti 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public NL = Nederlands 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public PL = polski 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public PT = português 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public RO = română 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public SK = slovenčina 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public SL = slovenščina 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public FI = suomi 10/09/2012  
Zoledronic acid Mylan : EPAR - Summary for the public SV = svenska 10/09/2012  

This EPAR was last updated on 13/01/2016 .

Authorisation details

Product details

Product details for Zoledronic acid Mylan
NameZoledronic acid Mylan
Agency product numberEMEA/H/C/002482
Active substance

zoledronic acid

International non-proprietary name (INN) or common name

zoledronic acid

Therapeutic area Fractures, Bone
Anatomical therapeutic chemical (ATC) code M05BA08
Generic

A generic medicine is a medicine which is similar to a medicine that has already been authorised (the 'reference medicine'). A generic medicine contains the same quantity of active substance(s) as the reference medicine. Generic and reference medicines are used at the same dose to treat the same disease, and they are equally safe and effective.

Publication details

Publication details for Zoledronic acid Mylan
Marketing-authorisation holder

Mylan S.A.S.

Revision5
Date of issue of marketing authorisation valid throughout the European Union23/08/2012

Contact address:

Mylan S.A.S.
117 allée des Parcs
F-69 800 Saint Priest
France

Product information

Product information

14/12/2015  Zoledronic acid Mylan -EMEA/H/C/002482 -IAIN/0010

Name Language First published Last updated
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016
Zoledronic acid Mylan : EPAR - Product Information SV = svenska 10/09/2012 13/01/2016

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013
Zoledronic acid Mylan : EPAR - All Authorised presentations SV = svenska 10/09/2012 28/08/2013

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

  • Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;
  • treatment of adult patients with tumour-induced hypercalcaemia (TIH).

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Zoledronic acid Mylan : EPAR - Procedural steps taken and scientific information after authorisation SV = svenska 28/08/2013 13/01/2016

Initial marketing-authorisation documents

Name Language First published Last updated
Zoledronic acid Mylan : EPAR - Public assessment report SV = svenska 10/09/2012  
CHMP summary of positive opinion for Zoledronic acid Mylan SV = svenska 22/06/2012  

Authorised

This medicine is approved for use in the European Union

More information on Zoledronic acid Mylan